Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-27
2005-12-27
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S235500, C514S255030, C544S124000, C544S360000, C546S139000, C546S193000, C546S208000
Reexamination Certificate
active
06979690
ABSTRACT:
This invention provides compounds of the formula (I) and (II):or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1is hydrogen or halo; R2and R3are independently hydrogen or C1-6alkyl; R4and R5are independently hydrogen or C1-6alkyl; R6is hydrogen, C1-12alkyl, C1-6alkoxy (C1-6)alkyl or C1-12alkyl substituted by up to 3 substituents selected from the groups consisting of C3-8cycloalkyl, aryl, heteroaryl and heterocyclic; R7and R8are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R9is C1-6alkyl or C3-8cycloalkyl; R10is C1-6alkyl or NR11R12; L is (CR11R12)nor NR11; M is NR11or (CR11R12)n; R11and R12are independently hydrogen or C1-6alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C1-6alkyl; with the proviso that when R9is C1-6alkyl, L is not NR11.These compounds have 5-HT4receptor binding activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans. This invention also provides a pharmaceutical composition comprising the above compound.
REFERENCES:
patent: 5137893 (1992-08-01), Becker et al.
patent: 5219850 (1993-06-01), Becker et al.
patent: 5434161 (1995-07-01), Becker et al.
patent: 5591749 (1997-01-01), Becker et al.
patent: 5604239 (1997-02-01), Becker et al.
patent: 5864039 (1999-01-01), Kawakita et al.
patent: 5968965 (1999-10-01), Dinsmore et al.
patent: 0504679 (1992-09-01), None
patent: 0274867 (1994-04-01), None
patent: 1217000 (2002-06-01), None
patent: HEI 1-258674 (1989-10-01), None
patent: 0967347 (1997-11-01), None
patent: 10203987 (1998-04-01), None
patent: 2001 6877 (2001-01-01), None
patent: WO 9100858 (1991-01-01), None
patent: WO 9215593 (1992-09-01), None
patent: WO 9308185 (1993-04-01), None
patent: WO 9407859 (1994-04-01), None
patent: WO 9408998 (1994-04-01), None
patent: WO 9605166 (1996-02-01), None
patent: WO 9631475 (1996-10-01), None
patent: WO 9727852 (1997-08-01), None
patent: WO 9738665 (1997-10-01), None
patent: WO 9950247 (1999-10-01), None
patent: WO 9950264 (1999-10-01), None
patent: WO 0105763 (2001-01-01), None
patent: WO 0114331 (2001-03-01), None
Tapia et al. “2,3-dihydro-2-oxo . . . ” CA 131:184899 (1999).
Courtemanche et al. “Polyfluoroalkyl . . . ” CA 135:226993 (2001).
Trilateral Project B3b :comparative sudy on reach-through claims (2001).
Dumuis, et al., “A 5HT Receptor in the Central Nervous System, Positively Coupled with Adnylate Cyclase, is Antagonized by ICS 205 930”,Eur. J. of Pharmacology, 146, pp. 187-188 (1988).
Dumuis, et al. “The Gastrointestinal Prokinetic Benzamide Derivatives are Agonists at the Non-classical 5-HT Receptor (5-HT4) Positively Coupled to Adenylate Cyclase in Neurons”,Naunyn-Schmiedeberg's Archives of Pharmacology, 340, 403-410 (1989).
Bockaert, et al., “The 5-HT4Receptor: A Place in the Sun”TiPs Reviews, vol. 13, pp. 141-145 (1992).
Ford, et al., “The 5-HT4Receptor”,Medicinal Research Reviews, vol. 13 (6), pp. 633-662 (1993).
Gullikson, et al., “Gastrointestinal Motility Responses to the S and R Enantiomers of Zacopride, a 5-HT4 Agonist and 5-HT3 Antagonist”,Drug Development Research, 26, pp. 405-417 (1992).
Eglen, et al., “Central 5-HT4Receptors”,TiPS Review, 16, pp. 391-398 (1995).
Bockaert, et al., “5-HT4 Receptors”,CNS Drugs, 1(1), pp. 6-15 (1994).
Romanelli, et al., “Synthesis and Biological Activity of a Series of Aryl Tropanyl Esters and Amides Chemically Related to 1H-Indole-3-carboxylic Acid endo 8-Methyl-8-azabicyclo[3.2.1]oct-3-yl Ester”,Arzneim-Forsch./Drug. Res. 43 (II) (8), pp. 913-918 (1993).
Kaumann, et al., “A 5-HT4-like Receptor in Human Right Atrium”,Naunyn-Schmiedeberg's Archives of Pharmacology, 344, pp. 150-159 (1991).
Mutterer, et al., “Haologenated pyridines v. fluorinated and brominated pyridine compounds”,Helvetica Chimica Acta, 59, Fasc. 1 (1976) No. 23-24, pp. 229-235 (Translation of German Article).
Barlow, et al., “Diels-Alder reactions of trichloro-1,2,4-triazine: intramolecular additions with 1,5 and 1,6 dienes”,J. Chem. Soc., Perkin Trans. 1, pp 519-524 (1995).
Lantos, et al., “Novel Cage Compounds from Inter-intra-molecular Diels-Alder Reactions of 1,2,4-Triazines with Cyclo-octa-1,5-diene”,J. Chem. Socl, Chem. Commun., pp. 1482-1483 (1988).
Greene, et al., “Protection for the Hydroxyl Group, including 1,2-and 1,3-Diols”,Protective Groups in Organic Synthesis, 2ndEdition, pp. 10-142 (1991).
Greene, et al., “Protection for the Amino Group”,Protective Groups in Organic Synthesis, 2ndEdition, pp. 309-405 (1991).
Greene, et al., “Protection for the Carboxyl Group”,Protective Groups in Organic Synthesis, 3rdEdition, pp. 369-377.
Feibush, et al., “Chirah Separation of Heterocyclic Drugs by HPLC: Solute-Stationary Phase Base-Pair Interactions”,J. Am. Chem. Soc., 108, pp. 3310-3318 (1986).
Baxter, et al., 5-Hydroxytryptamine, receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae,Naunyn-Schmiedeberg's Archives of Pharmacology, 343, pp. 439-446 (1991).
Mine, et al., “Comparison of Effect of Mosapride Citrate and Existing 5-HT4Receptor Agonists on Gastrointestinal Motility in Vivo and in Vitro ”,JPET, 283 (3), pp. 1000-1008 (1997).
Reeves, et al., “Investigation into the 5-hydroxytryptamine receptor mediating smooth muscle relaxation in the rat oesophagus”,Br. J. Pharmacol., 103, pp. 1067-1072 (1991).
Coldwell, et al., “The Synthesis, and Dopamine D2and Serotonin 5-HT3Receptor Affinity of 3-Aza Analogues (Pyridyl) of 4-Amino-5-chloro-2-methoxybenzamides”,Bioorganic&Medicinal Chemistry Letters, 5 (1), pp. 39-42 (1995).
Itoh, et al., “Synthesis and pharmacological evaluation of carboxamide derivatives as selective serotoninergic 5-HT4receptor agonists”,Eur. J. Med. Chem. 34, pp. 977-989 (1999).
Grob, et al., “Polar Substituent Effects in the Solvolysis of Primary and Tertiary Alkyl Halides, Polar Effect IX”,Helvetica Chimica Acta, 63, Fasc. 8, pp. 2152-2158 (1980).
Prugh, et al., “A Simple Method of Protecting a Secondary Amine with tert Butyloxycarbonyl (BOC) in the Presence of a Primary Amine”,Synthetic Communications, 22 (16), pp. 2357-2360 (1992).
Kimpe, et al., “A Convenient Synthesis of 1-Chloro-2-alkanones”,Synthesis, 2, pp. 188-190 (1987).
Blanco, et al., “Halogenation of Enol Silyl Ethers. Synthesis of Various Types of α-Bromocarbonyl Compounds”,Synthesis, pp. 194-196 (1976).
Lopez-Rodriguez, et al., “Benzimidazole Derivatives. Part 1: Synthesis and Structure-Activity Relationships of New Benzimidazole-4-carboxamides and Carboxylates as Potent and Selective 5-HT4Receptor Antagonists”,Bioorganic&Medicinal Chemistry, 7, pp. 2271-2281 (1999).
Klein, et al., “Design of a New Class of Orally Active Fibrinogen Receptor Antagonists”,J. Med. Chem., 41, pp. 2492-2502 (1998).
Turner, “Regiospecific Electrophilic Substitution of Aminopyridines: Ortho Lithiation of 2-, 3-, and 4-(Pivaloylamino) pyridines”,J. Org. Chem. 48, pp. 3401-3408 (1983).
Keenan, et al., “Conformational Preferences in Benzodiazephine Series of Potent Nonpeptide Fibrinogen Receptor Antagonists”,J. Med. Chem. 42, pp. 545-559 (1999).
Hirokawa, et al., “Synthesis ofN-(1-Ethyl-4-Methylhexahydro-1,4-Diazepin-6-YL)Nicotinamides and Their Affinities for 5-HT3and Dopamine D2Receptors”,Biorganic&Medicinal Chemistry Letters, 8, pp. 1551-1554 (1998).
Gymer Geoffrey
Kawamura Kiyoshi
Mihara Sachiko
Morita Mikio
Nukui Seiji
Benson Gregg C.
Chang Celia
Forman Frank W.
Pfizer Inc.
LandOfFree
Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3466963